ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1031

Orally Administered Cherry Juice Inhibits Localized Nfκb Activity and Histopathological Infiltrates in a Murine Model of Gout

Nicholas A. Young1, Peter Harb2, Ifeoma Okafor3, Caitlin Henry2, Emily Schwarz2, Kyle Jablonski4, Bianca Sandoval2, Wael Jarjour5 and Naomi Schlesinger6, 1Immunology and Rheumatology, The Ohio State University Wexner Medical Center, Columbus, OH, 2Rheumatology and Immunology, Columbus, OH, 3Rheumatology and Immunology, The Ohio State University Wexner Medical Center, Columbus, OH, 4The Ohio State University Wexner Medical Center, Columbus, OH, 5Department of Rheumatology and Immunology, The Ohio State University Wexner Medical Center, Columbus, OH, 6Department of Medicine, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: dietary supplements, gout, inflammation and inflammatory arthritis

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, October 22, 2018

Title: Innate Immunity Poster

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Gout is caused by the inflammation induced from the precipitation of monosodium urate (MSU) crystals in joints and is the most common inflammatory arthritis in the United States, occurring mostly in males and in up to 4% of the population. Since high levels of systemic uric acid and inflammation are both contributors to this chronic inflammatory condition, the pharmacological armamentarium includes both urate-lowering and anti-inflammatory therapeutic regimens. In adjunct to drugs to reduce inflammation, natural methods including dietary modifications and supplementation with nutraceutical compounds known to reduce inflammation have demonstrated some success in previous studies. In agreement, we have previously shown that cherry juice can reduce the incidence of flares in gout patients and significantly suppress IL-1β secretion in vitro in human cells. The objective of this study was to establish the anti-inflammatory influence of cherry juice in a murine model of gout to create a model experimental platform to use in future work investigating the molecular mechanism suppressing inflammation.

Methods:

Cherry juice concentrate was administered daily by oral gavage (240 µL/kg) to commercially available BALB/C-Tg(NFκB-RE-luc)-Xen mice that harbor a firefly luciferase cDNA reporter under the regulation of 3 NFκB responsive elements. After 14 days, gouty inflammation was induced by intra-articular injection of monosodium urate (MSU) crystals (0.5 mg) into the tibio-tarsal joint (ankle) under anesthesia. NFκB activity was measured locally in the injected ankle using the Xenogen in vivo imaging system (IVIS 200) and decalcified feet/ankles were paraffin-embedded and stained by H&E for histopathological analysis.

Results: Oral administration of cherry juice concentrate significantly reduced NFκB activity in mouse feet/ankles by IVIS analysis relative to control mice treated with PBS. Bioluminescent imaging signals correlating to NFκB activation and measured by total photon counts were inhibited almost 2-fold with the entire foot used as the region of interest in the analysis. Furthermore, histopathology by H&E showed a suppression of infiltrates into the space of the tibio-tarsal joint in mice receiving cherry juice concentrate when compared to PBS-treated control counterparts.

Conclusion:

The results of this study demonstrate a significant inhibition of inflammation, as measured by histology and NFκB activity, in the joint space of mice injected with MSU to induce gout; thereby recapitulating the conclusions of our previous work in human cells and gout patients and establishing a viable mouse model to use in future experiments delineating the molecular mechanism of this immunosuppressive response. Near future experiments include a comprehensive analysis of proinflammatory cytokines in the serum of these mice and long-term work will include in vitro assays investigating the effects of cherry juice concentrate on oxidative burst and IL-1β secretion following inflammasome activation.


Disclosure: N. A. Young, None; P. Harb, None; I. Okafor, None; C. Henry, None; E. Schwarz, None; K. Jablonski, None; B. Sandoval, None; W. Jarjour, None; N. Schlesinger, Astra Zeneca, 2,Novartis, Horizon, 5.

To cite this abstract in AMA style:

Young NA, Harb P, Okafor I, Henry C, Schwarz E, Jablonski K, Sandoval B, Jarjour W, Schlesinger N. Orally Administered Cherry Juice Inhibits Localized Nfκb Activity and Histopathological Infiltrates in a Murine Model of Gout [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/orally-administered-cherry-juice-inhibits-localized-nf%ce%bab-activity-and-histopathological-infiltrates-in-a-murine-model-of-gout/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/orally-administered-cherry-juice-inhibits-localized-nf%ce%bab-activity-and-histopathological-infiltrates-in-a-murine-model-of-gout/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology